Our study has observed a downregulation of netrin-1, a crucial factor for axon guidance (Croft et al., 2014), after MIN administration, supporting netrin-1 as a promising candidate for depression treatment (Zeng et al., 2017). Here, NTN1 is linked to depressive symptom measurement.